Latest news with #HONGKONG
New Paper
a day ago
- Sport
- New Paper
July 31 South Africa (Vaal) form guide
Race 1 (1,600m) (6) REDLIGHTGREENLIGHT is in form and can upstage those rivals in receipt of 3kg. (3) SINGLETON SAM and (4) THE LAST DUKE improved after a first outing as impressive maiden winners recently. Bear watching. (1) MIGHTY EAGLE and (2) RED PENNY let down a little when beaten by a subsequent Grade 2-placed runner over 1,400m. Stay with them on earlier form. Race 2 (1,200m) (1) ICONIC WINTER caught the eye last time in her second start back from a lengthy layoff. Could go one better. (4) BLUSHING BLOOM has improved with each outing and should be a factor after a career-best second last time. (7) RINGA RINGA ROSES and (10) TWELFTH OF NEVER are not taken lightly on debut. Race 3 (1,200m) (1) XENOPHON is due for a win soon on the strength and consistency of his form. (11) POWER OF PEARLS ran a fast-finishing third over 1,000m on debut. Open to improvement following a 186-day absence. Younger rivals (8) CAPTAIN FRANK and (9) GAVIUS MAXIMUS fit a similar profile, so should not be underestimated. Race 4 (1,600m) (8) RADIO STAR stayed on for fifth in 1,400m race after a second in both previous outings over the same distance against older opposition. The step-up in trip will suit. (7) MATROOSBERG and (6) LUWAK, a pleasing debut third, are also likely to improve. (4) BEST CANDIDATE will improve on his debut sixth. Race 5 (1,600m) (8) BABETTE'S FEAST was rather one-paced on debut. Can improve. (3) MATTIAZO is knocking on the door. Solid claims. (10) WITCHING HOUR should have a role to play after a career-best second over this trip last time. (2) NKWENKWEZI has the form and experience to make her presence felt but is vulnerable to less-exposed types. Race 6 (1,450m) (3) MISS LIA makes her reappearance from a six-month layoff following her no-show in a 3yo Fillies Grade 2. She won after a three-month break last year, so does run well fresh. (8) DESTINY OF FIRE is capable of better than her recent performances suggest, so she should not be taken lightly at this level of her current rating. (9) HONG KONG and (10) EXCEEDINGLY GLAM are also dangerous to discount at the bottom of the weights. Race 7 (1,450m) (1) TOO LATE MY MATE deserves a reward for her consistency and this drop in class represents an ideal opportunity for her to end a 522-day winless run. (2) LADY SABRINA, (5) WHIRLYBIRD and (6) MAVERICK QUEEN seem most likely dangers. Race 8 (1,450m) (5) PALACE PRINCE is an up-and-comer whose progress should be worth following. (1) FOSTINOVO ran fifth at Turffontein on July 26. Every chance if taking his place at this lower level with a 1.5kg-claimer up. (2) CRESCENDO had excuses for his disappointing last start and a subsequent 75-day break would have done him good. Hard-knockers (3) AFTER HOURS cannot be ignored at this level but is vulnerable to less-exposed, improving types.
Reuters
3 days ago
- Automotive
- Reuters
Breakingviews - Samsung's $16.5 bln Tesla coup comes with caveats
HONG KONG, July 29 (Reuters Breakingviews) - Samsung Electronics ( opens new tab finally has some good news. In posts on his X social media platform on Sunday, Tesla (TSLA.O), opens new tab CEO Elon Musk detailed, opens new tab that his carmaker has struck a $16.5 billion deal to buy state-of-the-art chips from the South Korean group. Yet the impressive coup, which pushed Samsung's stock up 7% on Monday, comes with some caveats. First, on an annual basis, it works out to $2.1 billion in sales over the agreement's eight-year span. That's nowhere near enough to turn things around at Samsung's foundry business. Its operating loss topped 5 trillion won ($3.6 billion) in the first quarter and widened in the second quarter, estimates Fitch Ratings' Shelley Zhang. Granted, Musk also said that the contract, which includes advanced A16 chips, "is just the bare minimum" and demand could end up being "several times higher". But Musk is notorious for over-egging production estimates. Even if he's right, Tesla's patronage is unlikely to be enough to turn around Samsung's foundry fortunes alone. That'll require Chair Jay Y. Lee finding ways to parlay Musk's leap of faith into a broader contract chip-manufacturing business able to snatch share from the $1 trillion market leader TSMC ( opens new tab. That may not be straightforward. An unusual decision to allow Musk to walk production lines and work with Samsung to 'maximize manufacturing efficiency' could force the company to share crucial know-how. That might put off other potential customers. Tesla is a risky partner in other ways, too. Last week, Musk said that the company faces a 'few rough quarters' given waning U.S. support for battery power. The electric-vehicle maker is also losing share in China and Europe. Long-term bets, including robotaxis and the Optimus robot, are not necessarily going to fill the gap. Meanwhile, Samsung is under pressure to show it can execute. Its high bandwidth memory chips failed tests set by another key customer, Nvidia (NVDA.O), opens new tab, due to heat and power consumption problems, Reuters reported last year. Although it has been able to develop cutting-edge chips like the 2-nanometre device Musk needs, ensuring high yield and quality at scale is tough. Making the chips at an untested U.S. plant adds further uncertainty. Falling short would jeopardise the project's profitability, as well as whether or not Tesla sticks with them. Lee will welcome Tesla on board, but he'd be wise to buckle up for the ride. Follow @KatrinaHamlin, opens new tab on X
Yahoo
3 days ago
- Business
- Yahoo
A Blueprint for Beauty: Meiyume Indonesia's Interactive Showcase Brings Insights-driven Innovation to Life
HONG KONG, July 29, 2025 /PRNewswire/ -- Meiyume, an ODM and OEM leader in the beauty industry, invites beauty brands to explore "Your Beauty Blueprint: From Insights to Impact," an exclusive private showcase taking place on 5–6 August 2025 at its Indonesia manufacturing plant. Designed as an interactive experience, the event offers beauty brands a firsthand look at Meiyume's latest insights-led innovations across colour, skincare, bodycare, and more — powered by the Beauty Intelligence Platform (BIP). Attendees will explore Meiyume's end-to-end capabilities in formulation, packaging, and turnkey manufacturing through trend presentations, live demos, and expert-led conversations. 2025 Innovation Collection: Meiyume will introduce four targeted ranges designed to meet the evolving needs of beauty consumers across Southeast Asia — each thoughtfully crafted using trending ingredients and emerging claims identified through Meiyume's BIP. These collections offer brands a springboard to develop relevant, on-trend products that meet today's market expectations and consumer desires. Intercos x Meiyume: A curated range of trend-driven colour and skincare innovations, this collection marks the first official showcase since the strategic alliance between Intercos and Meiyume earlier this year. Featuring Halal-compliant, sensorial formulas, it is thoughtfully crafted for the Southeast Asian beauty consumer. Longevity: This targeted skincare range combines cutting-edge biotech with gentle, skin-compatible innovation to strengthen the skin barrier, promote resilience, and preserve a natural, radiant glow—before the first signs of ageing appear. NovaTouch: This thoughtfully developed body care collection is designed to support women through pregnancy and postpartum, combining science-backed and natural ingredients to deliver both safety and performance. BloomTots: This gentle, science-backed skincare and haircare range for babies and young children supports microbiome balance, barrier repair, and daily protection against environmental stressors. The showcase also features GAIA, Meiyume's latest packaging innovation that merges sophistication with sustainability, and HORISUN, a curated selection of trend-driven suncare packaging solutions. These collections are part of Meiyume's library of stock innovations, each ready for customisation and commercialisation. Beauty Intelligence Platform (BIP): Meiyume's 2025 ODM collection is guided by its proprietary BIP — a sophisticated AI system that analyses real-time data across product, packaging, and ingredient trends. This ensures every formulation is insight-led, relevant, and aligned with evolving consumer demands. A Blueprint for Innovation This is more than a product unveiling — it's an immersive journey into Meiyume's world of end-to-end beauty innovation. Through live demonstrations, expert presentations, and optional guided tours, attendees will experience how Meiyume supports brands from insight to execution. From discovering the direction with data-led insights, to building the solution with trend-driven formulation and packaging, to powering the production through their global manufacturing network — this showcase invites beauty brands to envision how their next breakthrough can take shape. Whether launching a new line or expanding an existing one, Meiyume invites brands to explore how we can bring their next beauty breakthrough to life. Interested visitors are invited to contact Meiyume for more information or to RSVP. About Meiyume: Meiyume is a global OEM, ODM and packaging leader in the beauty industry, providing smart end-to-end solutions that drive success for brands. With a focus on sustainability, innovation, and quality, Meiyume delivers exceptional value to beauty brands, big or small. Raya Bogor KM 28, Jakarta 13710, Indonesia View original content to download multimedia: SOURCE Meiyume Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
SHANGHAI and HONG KONG, July 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17th to October 21st at the Messe Berlin in Berlin, Germany. Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate)Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH)Abstract Number: 2907Presentation Number: 2113PDate: October 19, 2025 About ATG-022 ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight junctions between cells, forming a barrier to regulate cell permeability. However, in cancer, Claudins are aberrantly expressed on the cell surface due to changes in cell polarity. CLDN18.2 is frequently overexpressed in a range of primary malignant tumors, including gastric, esophageal, cholangiocarcinoma, and pancreatic cancers. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATG-022, for gastric and pancreatic cancers. Data from the ongoing CLINCH study demonstrated that ATG-022 delivers robust efficacy across all levels of CLDN18.2 expression in gastric cancer patients, including those with high, low, and ultra-low expression. This broad activity positions ATG-022 as a potential market leader, capable of addressing the largest patient population with CLDN18.2-positive tumors. Furthermore, the strong efficacy observed in patients with low CLDN18.2 expression suggests promise for treating other tumor types with similar expression profiles. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Mobile: +86 13062747000 View original content to download multimedia: SOURCE Antengene Corporation Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
6 days ago
- Politics
- Washington Post
Taiwan votes to decide whether to oust lawmakers from China-friendly party in closely watched poll
HONG KONG — Taiwanese were voting Saturday to determine whether to oust about one-fifth of their lawmakers, all from the opposition Nationalist Party, in elections that could potentially reshape the power balance in the self-ruled island's legislature. The independence-leaning ruling Democratic Progressive Party won last year's presidential election , but the China-friendly Nationalists, also known as the KMT, and the smaller Taiwan People's Party have enough seats to form a majority bloc.
